^
Association details:
| Biomarker: | MSH2 deletion |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + MEDI0680 (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations
Excerpt:
MMR deficiency phenotype was confirmed by the absence of MSH2 and MSH6 as well as deleterious mutations in these genes. IHC staining for programmed cell death ligand-1 [PD-L1] revealed 2+ staining in 80 % of cells. The patient gained access to combination immunotherapy trial utilizing MEDI4736 and MEDI0680 through a clinical trial. The patient achieved a prolonged, complete remission within two months and had no severe ill effects from the treatment.
DOI:
10.1186/s40425-015-0104-y
Trial ID:
